NVS•benzinga•
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Summary
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 30, 2025 by benzinga